Data from clinicaltrials.gov - Curated by EPG Health - Last updated 10 January 2020
This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
NanoPac is very small (submicron) particles of the chemotherapy drug, paclitaxel, which is administered intravenously in a number of types of cancer. These submicron particles are injected directly into solid tumors to target cancer at the site of disease with less systemic exposure than intravenously administered chemotherapy. In this study, this submicron particle paclitaxel will be injected directly into the prostate lesion in men with prostate cancer scheduled for prostatectomy on up to three different occasions. All subjects in the study will receive NanoPac and will be evaluated to see if NanoPac is safe, well-tolerated, and has an impact on prostate cancer.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 18 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Open-label, single group, safety, efficacy, and pharmacokinetic study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Trial of NanoPac Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy
Estimated Study Start Date: March 2020
Estimated Primary Completion Date: December 2021
Estimated Study Completion Date: January 2022
- Experimental: NanoPac
|Date last updated at source||08-Jan-20|
|Study start date||01-Mar-20|
|Estimated primary completion date||01-Dec-21|